Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis.
- DOI
- 10.1038/s41598-024-79918-7
- Published
- 2024 Nov 18
- Container
- Scientific reports
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41598-024-79918-7,
title = {Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis.},
author = {Ma J and Zhang H and Zhao J and Su M and Feng Y and Yuan X and Liu D and Pang X and Zhao R and Wang J and Duan W and Chang X and Guo J and Zhang W},
year = {2024},
journal = {Scientific reports},
doi = {10.1038/s41598-024-79918-7},
url = {https://doi.org/10.1038/s41598-024-79918-7}
}RIS
TY - JOUR TI - Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis. AU - Ma J AU - Zhang H AU - Zhao J AU - Su M AU - Feng Y AU - Yuan X AU - Liu D AU - Pang X AU - Zhao R AU - Wang J AU - Duan W AU - Chang X AU - Guo J AU - Zhang W PY - 2024 JO - Scientific reports DO - 10.1038/s41598-024-79918-7 UR - https://doi.org/10.1038/s41598-024-79918-7 ER -
APA
J, M., H, Z., J, Z., M, S., Y, F., X, Y., D, L., X, P., R, Z., J, W., W, D., X, C., J, G., & W, Z. (2024). Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis.. Scientific reports. https://doi.org/10.1038/s41598-024-79918-7
Source records
- pubmed · retrieved 2026-09-26T15:16:19.301Z